Lakefront Biotherapeutics NV (GLPG) Form 6-K — Oct 14, 2026
Lakefront Biotherapeutics completed the sale of its preclinical CAR-T cell therapy programs to Belgium-based Armed Cell Therapeutics, founded by Paul Stoffels, John Mellors and Peter Verhaeghe. The deal includes an €8 million upfront payment, up to $230 million in milestone payments, and a low-single-digit royalty to Lakefront. The technology was originated by AboundBio, which Lakefront (formerly Galapagos NV) acquired in 2022, and comprises armed CAR-T constructs for hematological and solid tumors.
Key figures
- Deal Value Usd
- €8 million upfront plus up to $230 million in milestones plus low-single-digit royalty
- Upfront Payment
- €8 million
- Milestone Payments
- up to $230 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.